MedTrace Logo

Adacel® Booster Vaccination for CMI Assay Development

NCT04543669 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-09-10

No results posted yet for this study

Summary

Recruitment of individuals primed during childhood with TdaP (tetanus, diphtheria , acellular pertussis) vaccine, and administration of an Adacel booster with blood sample collection at various time points before and after vaccination.

Collection of blood sample volumes will be large enough to allow assessment and comparison of multiple assays that evaluate cell-mediated immune (CMI) responses and other biomarkers following the administration of pertussis vaccinations. The ultimate objective would be to utilize these validated assays for evaluation of pertussis clinical trial results or development of new pertussis vaccine formulations.

Conditions

  • Pertussis

Interventions

BIOLOGICAL

Adacel®

Vaccine for TdaP-Tetanus, diphtheria, acellular pertussis

Sponsors & Collaborators

  • Sanofi Pasteur, a Sanofi Company

    collaborator INDUSTRY

  • VaxDesign Corporation

    collaborator UNKNOWN

  • Dalhousie University

    lead OTHER

Principal Investigators

  • Scott A Halperin, MD · Dalhousie

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-12
Primary Completion
2017-09-20
Completion
2017-09-20

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04543669 on ClinicalTrials.gov